BIOL (Biolase, Inc.) Market Value to Book Value Ratio

Biolase, Inc. (BIOL) - corporate logo

BIOLASE, Inc. (BIOL) is undergoing a rigorous financial restructuring and asset divestiture to preserve capital. The current market-to-book ratio reflects the business value dynamics, where -0.65 indicates the level of this metric. The laser dentistry leader holds a massive patent portfolio, offering painless treatment. The company generates steady income from equipment maintenance and the regular sale of consumables.

Market Capitalization to Net Assets: Biolase Inc. (BIOL) for 07/04/2022 - 08/04/2024
Finished products of BIOLASE Inc.

To protect capital during periods of turbulence, it is essential for investors to assess the real value of assets. This ratio compares the market price of BIOL with its net assets, measuring management's ability to create added value. By analyzing the current level of the company's value relative to its book capitalization, unjustified premiums can be identified. For BIOLASE, Inc. (BIOL), this is critical, as an independent product cycle and stable demand for medtech should provide fundamental support for the share price.

Direct competitors

Boston Scientific (BSX) - Market Value to Book Value Ratio|EW (edwards.com) - Market Value to Book Value Ratio|RMD: Market Value to Book Value Ratio|Market Capitalization to Book Value PODD|ZBH - Market Value to Book Value Ratio|Market Capitalization to Net Assets CooperSurgical (COO)|ALGN: Market Capitalization to Book Value Ratio|Market-to-Book Ratio globusmedical.com GMED|TMDX: Market Capitalization to Book Value Ratio|ATEC - Market Cap to Net Assets Ratio|Artivion Inc - Market Capitalization to Book Value Ratio|Enovis Inc. (ENOV) - Market Capitalization to Book Value|IART (Integra LifeSciences) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio ESTA|Market Value to Book Value Ratio Beta Bionics (BBNX)|Market Value to Book Value Ratio IRADIMED Corp (IRMD)|Market Capitalization to Book Value Ratio EMBC|TNDM - Market Capitalization to Book Value|Market Cap to Net Assets Ratio AxoGen, Inc.|SIBN - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio OFIX|Bioventus Inc (BVS) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio OrthoPediatrics Corp (KIDS)|Capitalization to Book Value Ratio Treace Corp (TMCI)|Strata Critical Medical Inc (SRTA) - Market Cap to Net Assets Ratio|Market Value to Book Value CARL (carlsmed.com)|RxSight - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio ClearPoint Neuro Inc. CLPT|STXS (Stereotaxis Corp) - Market Capitalization to Book Value Ratio|STIM - Market-to-Book Ratio|Market Capitalization to Book Value Ratio Sight Sciences, Inc.|orchestrabiomed.com (OBIO) - Capitalization to Book Value Ratio|ANIK: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value InspireMD Inc|Market Capitalization to Book Value Ratio ZJYL (Jin Medical International)|Market Cap to Net Assets Ratio vivani.com (VANI)|Market Capitalization to Book Value Ratio XTNT (Xtant Medical)|n1mtc.com - Market Capitalization to Book Value Ratio|MODD - Market Value to Book Value Ratio|Myomo Inc. (MYO) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Envoy Medical, Inc COCH|Vivos Therapeutics Inc (VVOS) - Market Value to Book Value|Market Capitalization to Book Value Ratio NVNO (enVVeno Medical)|Market-to-Book Ratio SINT|TNON: Market Value to Book Value Ratio|Market Value to Equity Ratio ReWalk Robotics LFWD|Market Cap to Net Assets Ratio AMIX (Autonomix Medical)|Market Capitalization to Book Value Ratio INVO Fertility Corp IVF|Market Capitalization to Book Value Ratio BBLG (Bone Biologics)|AXNX: Market Capitalization to Book Value|Market Value to Book Value Ratio dynatronics.com (DYNT)|FNA (Paragon 28) - Market Capitalization to Net Assets|Market Value to Book Value Ratio INVO